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Inherited episodic neurological disorders are often due to mutations in ion channels or their interacting
proteins, termed channelopathies. There are a wide variety of such disorders, from those causing paralysis,
to extreme pain, to ataxia. A common theme in these is alteration of action potential properties or synaptic
transmission and a resulting increased propensity of the resulting tissue to enter into or stay in an altered
excitability state. Manifestations of these disorders are triggered by an array of precipitants, all of which
stress the particular affected tissue in some way and aid in propelling its activity into an aberrant state. Study
of these disorders has aided in the understanding of disease risk factors and elucidated the cause of clinically
related sporadic disorders. The findings from study of these disorders will aid in the diagnosis and efficient
targeted treatment of affected patients.Introduction
Episodic disorders are common in humans and represent
a diverse and interesting group of diseases. These disorders
seem, at first, largely disparate; movement disorders, cardiac
arrhythmias, and migraines are typically not grouped together.
With further examination, however, these disparate disorders
are actually closely related in their biophysical underpinnings.
Many channelopathies are simple Mendelian disorders, making
them amenable to genetic mapping, though, as discussed
below, this is not always the case.
A Variety of Phenotypes Affecting Different Cell Types
Ion channels are expressed broadly throughout the body. While
there are a number of channelopathies, such as polycystic
kidney disease, focal segmental glomerulosclerosis, and
x-linked congenital stationary night blindness, that either affect
nonexcitable cells or are nonepisodic in nature, this review
focuses on the large number of episodic channelopathies of
muscles and neurons.
Skeletal Muscle
The first delineated and most paradigmatic of the channelopa-
thies are those resulting in primary skeletal muscle disorders.
These disorders form a spectrum frommuscle hyper- to hypoex-
citability, with hyperexcitable muscle manifesting clinically as
myotonia and hypoexcitability as weakness or paralysis. At the
far hyperexcitable end of this spectrum is myotonia congenita.
Myotonia congenita is also one of the few channelopathies
with both dominant and recessive forms, Thomsen disease
and Becker generalized myotonia, respectively (Koch et al.,
1992; Lossin and George, 2008). These patients complain of
‘‘stiffness’’ after resting for a period of time, and this improves
with continued movement, which is referred to as the warm-up
phenomenon.
Both hyperkalemic periodic paralysis (hyperKPP), the first
characterized human channelopathy, and hypokalemic periodic
paralysis (hypoKPP) result in weakness or paralysis. HyperKPP282 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.is thus named because attacks can be precipitated by adminis-
tration of potassium. During attacks, serum potassium may be
elevated but is often normal (Pta´cek et al., 1991; Rojas et al.,
1991). Regardless of the serum potassium level during an attack,
potassium administration will uniformly induce a bout of weak-
ness. These patients often have muscle hyperexcitability
(myotonia) at rest or following activity. Monitoring a patient
clinically or by electromyography (EMG) during the evolution
of an attack shows that myotonia is present and diminishes
as hyperexcitability transitions into inexcitability or paralysis.
As hyperKPP patients age, some develop progressive fixed
weakness (myopathy) in the affected limbs.
Not all skeletal muscle channelopathies lead to myotonia.
HypoKPP patients show low serum potassium levels during
bouts of weakness, and attacks can be induced by lowering
serum potassium (e.g., by administering glucose and insulin,
which drive potassium into muscle) (Bulman et al., 1999; Jurkat-
Rott et al., 1994; Pta´cek et al., 1994). However, these patients
never showmyotonia. Aswith hyperKPP, somehypoKPPpatients
develop progressive fixed weakness in the affected limbs.
Another potassium-sensitive phenotype is potassium-aggra-
vated myotonia (PAM). These patients have myotonia that is
precipitated or worsened by administration of potassium, but
these patients never develop episodic weakness. That is, the
hyperexcitability never transitions into inexcitability.
Paramyotonia congenita (PMC) is similar to hyperKPP in that
patients generally manifest signs of both hyperexcitability
(myotonia) and inexcitability (episodic weakness) (Heine et al.,
1993; McClatchey et al., 1992; Pta´cek et al., 1992). However,
attacks are not precipitated by administration of potassium.
Rather, muscle cooling leads to prominent myotonia that often
transitions to weakness. Unlike the warm-up phenomenon in
myotonia congenita, myotonia in these patients often worsens
with repeated muscle use. Thus, it is called paradoxical
myotonia. PMC mutations represent one of the rare forms of
temperature-sensitive mutations seen in humans.
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myotonia/episodic weakness is seen but attacks can be precip-
itated by both potassium administration and muscle cooling.
This appears to be a distinct but hybrid phenotype of
hyperKPP/PMC (de Silva et al., 1990).
Neuromuscular Junction
Abnormalities of muscle function can also arise at the level of the
neuromuscular junction and include the congenital myasthenic
syndromes (CMS). There are actually three categories of CMS,
affecting (1) the presynaptic membrane (nerve), (2) the synaptic
cleft, or (3) the postsynapticmembrane (muscle end plate). There
are a wide range of clinically distinguishable varieties, each with
a different molecular etiology (Engel et al., 2010). All of these
alterations result in altered synaptic processing.
Peripheral Nerve
Channelopathies are not restricted to disorders of muscle or
neuromuscular junction. A triad of pain perception disorders
have recently been described that can result in either absence
of or hypersensitivity to painful stimuli (Fischer and Waxman,
2010). Primary erythermelalgia is characterized by bouts of
burning pain, flushing, and swelling of the feet, hands, and some-
times other areas (Yang et al., 2004). A related disorder, parox-
ysmal extreme pain disorder (PEPD), is characterized by pain
and flushing in the submandibular, ocular, and rectal areas (Fer-
tleman et al., 2006; Fertleman et al., 2007). On the opposite end
of the pain spectrum is congenital insensitivity to pain (CIP), also
termed channelopathy-associated insensitivity to pain (Cox
et al., 2006). Though not an episodic disorder, CIP results in
the complete loss of pain sensation concomitant with neurop-
athy. While this may at first seem somewhat appealing, individ-
uals with this disorder commonly (and unknowingly) suffer
broken bones and tend to accrue injuries to their lips and tongue
due to frequent, inadvertent biting during youth.
Brain
There are a variety of episodic disorders of the brain caused by
channel mutations. These can be broadly broken into three cate-
gories: paroxysmal movement disorders, epilepsies, and head-
ache disorders. Paroxysmal movement disorders are exemplified
by the episodic ataxias and paroxysmal dyskinesias, each with
several distinct subtypes. Inherited episodic ataxias are rare, auto-
somal-dominant disorders of cerebellar motor coordination (Jen
et al., 2007). The various subtypes are distinguished to some
extent by clinical differences (e.g., duration of ataxic bouts and
thepresenceor absenceof associatedsymptomssuchasmyoky-
mia or visual disturbances) and by their genetic cause (genemuta-
tionand/orgenetic localization).Episodicataxia type2 (EA2) isalso
genetically and clinically overlapping with spinocerebellar ataxia
type6 (SCA6)andgenetically, but only rarely clinically, overlapping
with familial hemiplegic migraine type 1 (see below). Paroxysmal
dyskinesias are typified by bouts of involuntarymovement (Mu¨ller,
2009). Specific paroxysmal dyskinesias are distinguished by
both their underlying genetics and their symptoms and triggers.
Paroxysmal nonkinesigenic dyskinesia, for instance, presents as
occasional attacks of dystonia, chorea, or athetosis that can be
precipitated by stress or ingestion of coffee or alcohol (Lee et al.,
2004).
Epilepsies are themselves a very broad category of episodic
neurologic disorders that can arise from many causes, includingmetabolic brain disorders, abnormalities of cortical develop-
ment, brain trauma, or structural lesions of the brain, such as
brain tumors. The idiopathic epilepsies are defined as those
with apparently normal brain (by imaging) and for which no
other cause is recognized. Some of these are heritable and
include generalized epilepsy with febrile seizures plus related
disorders (GEFS+), autosomal-dominant nocturnal frontal
lobe epilepsy (ADNFLE), benign febrile neonatal convulsions
(BFNC), and generalized epilepsy with paroxysmal dyskinesia
(GEPD). Not surprisingly, these have also been shown to be
channelopathies.
GEFS+ is a syndromic disorder and encompasses severe
myoclonic epilepsy of infancy (SMEI), borderline SMEI, and
intractable epilepsy of childhood (Hirose et al., 2005; Nakayama,
2009). Seizures in GEFS+-afflicted individuals can vary widely,
including afebrile tonic-clonic, absence, and myoclonic types.
SMEI is genetically related to GEFS+, but its presentation in
patients is much more severe and it results in developmental
delay. ADNFLE is a rare epilepsy disorder characterized by
complex motor seizures during sleep, often including vocaliza-
tions. GEPD is a hybrid of epilepsy and paroxysmal dyskinesia,
wherein patients have tonic-clonic or absence seizures as well
as signs of paroxysmal dyskinesia (Du et al., 2005).
While many types of migraine have genetic components,
familial hemiplegic migraine (FHM) is one of the fewwith a simple
autosomal-dominant mode of inheritance. FHM is characterized
by bouts of migraine with aura associated with hemiparesis and,
in some cases, cerebellar degeneration. The subtypes of FHM
can be distinguished by both their underlying genetic mecha-
nism and, in a few rare cases, the presence of cerebellar
dysfunction (Pietrobon, 2010).
Heart
There are numerous types of inherited cardiac arrhythmias
caused by ion channel mutations (Campuzano et al., 2010).
These include atrial fibrillations and at least a dozen types of
long QT (LQT) syndrome. Elongation of the QT interval results
in ventricular tachyarrhythmia and can lead to sudden death.
While the channelopathies presented so far have affected
a single organ system, this is not always the case. The clinical
manifestation of Andersen-Tawil syndrome (ATS) is broad, con-
taining cranial, facial, cardiac, skeletal muscle, and neurocogni-
tive symptoms (Plaster et al., 2001; Tristani-Firouzi and Ether-
idge, 2010; Yoon et al., 2006a; Yoon et al., 2006b). The most
striking dysmorphic features are widespread eyes, cleft palate,
and syndactyly of the toes. ATS patients also have intermittent
bouts of weakness or paralysis like those seen in the other
familial periodic paralyses. ATS is also a subtype of LQT
syndrome, mentioned above. Determination of its genetic cause
has led to the supposition that ATS may also have neurological
symptoms. Recent studies have, indeed, found neurological
symptoms such as deficits in executive function and abstract
reasoning (Yoon et al., 2006a). Like ATS, Jervell and Lange-
Nielson syndrome (J-LN) is also a multisystem channelopathy
and is a LQT syndrome variant. J-LN patients have cardiac
arrhythmia concomitant with deafness rather than skeletal
muscular or other developmental disorders (Schwartz et al.,
2006). Another interesting multisystem channelopathy, Timothy
syndrome, is further discussed below (Splawski et al., 2004).Neuron 68, October 21, 2010 ª2010 Elsevier Inc. 283
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Figure 1. Episodic Disorders Are Caused by the Increased Relative
Stability of, or Decreased Barrier for Entry into, an Aberrant State
Episodic-disease-related mutations result in one of two possible alterations.
They can change the relative stability of the normal and one or more aberrant
states. The equilibrium between the two states is then shifted toward the aber-
rant state. Alternatively, they may result in the increased ability of a stressor to
move the system from the normal to an aberrant state. An example of this
would be some TPP mutations, which result in altered physiology only during
thyrotoxicosis (Ryan et al., 2010).
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One of the unusual aspects of many channelopathies is their
paroxysmal nature. These patients often appear completely
normal between attacks because of homeostatic mechanisms
regulating membrane excitability. A common precipitant for all
of the episodic disorders presented here is stress of some
form. For some channelopathies, such as the periodic paralyses,
rest after exercise or fasting can provoke attacks. For others,
warm temperatures (erythermelalgia), consumption of certain
foods that raise or lower serum potassium (periodic paralyses),
or drinking caffeine or alcohol (paroxysmal nonkinesigenic dyski-
nesia) can precipitate attacks.
When considering how episodic disorders are triggered, it can
be helpful to consider the episodic phenotype as one or more
stable states separated by a barrier (Figure 1). In this model,
the stressor serves to propel the current state over the instability
barrier into an aberrant state. For some disorders, this aberrant
stable state exists in even normal individuals (Jurkat-Rott et al.,
2009). An example of this would be migraine, where sufficient
provocation seems to be able to trigger a migraine in otherwise
normal individuals. For other disorders, such as thyrotoxic hypo-
kalemic periodic paralysis (TPP), the mutations may instead be
increasing the stability of a normally unstable aberrant state
rather than increasing the propensity of triggers to alter the state
(Ryan et al., 2010). Other possibilities include altering the stability
of the normal state or some combination of these alterations.
Formal dynamical analysis of episodic disorders like that sug-
gested here has, in fact, proven helpful in understanding their
pathophysiology (Cannon et al., 1993) andmay aid in developing
useful therapies. In brief, homeostatic mechanisms are normally
able to maintain neurotransmission and both cellular and
network excitability within normal limits. Alteration of ion chan-
nels decreases the safety margins, thus stressing homeostatic
mechanisms such that a normally innocuous stimulus proves
pathogenic.284 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.An interesting aspect of channelopathies is that they tend to
present clinically in childhood and worsen with maturation,
followed by amelioration with further aging. In some cases this
seems to be due to differences in splice-form expression during
development, such as with erythermelalgia (Choi et al., 2010). In
other cases, this is likely due to hormonal changes, though the
exact mechanisms are largely unclear. The best-known example
of the affect of hormones on an episodic disorder would be the
increased incidence of migraines during menses (Martin and
Lipton, 2008). Another strong example of the influence of
hormones on an episodic disorder is TPP, in which treatment
of the underlying thyrotoxicosis is sufficient to prevent attacks
of episodic weakness. Furthermore, attacks can either increase,
as seen in PMC in at least one patient (de Silva et al., 1990), or
decrease, as seen in some hyperKPP patients (Finsterer,
2009), with pregnancy. Hormones may also help to explain the
gender disparities seen in the prevalence of some episodic dis-
orders. The exact manner in which hormones influence episodic
disorders remains to be elucidated.
Ion Channels in Multiprotein Complexes
Ion channels serve as the basis by which ions traverse cell
membranes to elicit electrical excitability (Hille, 2001). They
accomplish this task by forming ion-selective pores through
the membrane. Ion channels are highly conserved across all
living species and may be broadly divided into three categories:
voltage-gated, ligand-gated, and others (such as inwardly recti-
fying potassium channels).
Of thevoltage-gatedchannels, thesodium,calcium,andpotas-
sium channel families have received themost study. The voltage-
gated potassium (KV) channels are a large family of proteins
composed of six transmembrane a helices (S1–S6), with S4
serving as the voltage sensor and a pore-forming loop between
S5andS6 (Figure2). A functional potassiumchannel is composed
of four such subunits, inwhich each subunit need not be identical,
termedheteromultimerization (Gutmanet al., 2005). Sodium (NaV)
and calcium (CaV) channels are structurally similar, with the
exception that a single transcript contains four internally homolo-
gous domains, each equivalent to a voltage-gated potassium
channel subunit (Figure 2) (Catterall et al., 2005a; Catterall et al.,
2005b). Not surprisingly, each type of channel also has auxiliary
subunits that function to modify trafficking, localization, and/or
physiologic properties.Chloride channels are structurally distinct,
and one has recently been crystallized (Dutzler et al., 2003).
A functional chloride channel is composed of two subunits, which
can gate either together or independently (Duran et al., 2010).
Sodium channels can be generally thought of as generating
the upstroke of the action potential. Voltage-gated potassium
channels, on the other hand, are largely responsible for repolariz-
ing themembrane and halting an action potential. Calcium chan-
nels often do not contribute greatly to action potential generation
and propagation but, instead, bridge cellular excitability with
intracellular signaling and are vital for excitation-contraction
coupling and synaptic release. Chloride channels, finally, often
function to set baseline excitability by acting as a current shunt.
Sodium Channel Disorders
Gating describes the voltage or other properties that affect the
activation, deactivation, and inactivation of channels. A common
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Figure 2. Mutations in Many Classes of Ion Channels Are Associated with Human Disease
Voltage-gated potassium (KV) channels are composed of four subunits. Each subunit is composed of six transmembrane segments (S1–S6) and intracellular N
and C termini. The ion-conducting pore of the channel is formed by S5 and S6 of the four subunits, the ion selectivity filter by the S5–S6 loop. S4 functions as the
voltage sensor. Inward-rectifier potassium (Kir) channels are similar but lack the first four transmembrane segments. Voltage-gated sodium (NaV) and calcium
(CaV) channels are, in essence, four tandem repeats of a voltage-gated potassium channel. Because of their tetramerization, potassium channels can have domi-
nant-negative mutations. Under each channel name is an abbreviated list of human neurological disorders resulting from mutations in such channel genes.
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sodium channels, is alteration of the gating kinetics to produce
aberrantly large currents. In hyperKPP, some mutations in the
NaV1.4 sodium channel (e.g., L689I) result in activation at more
hyperpolarized potentials coupled with slowed inactivation.
The addition of this noninactivating current results in mutant
channels not slowly depolarizing the membrane but, rather,
rapidly depolarizing it such that action potential initiation is
blocked (Bendahhou et al., 2002). Interestingly, mutations in
the same channel can also lead to PMCandPAM, demonstrating
that the exact nature and magnitude of alteration due to an indi-
vidual mutation can lead to quite different clinical phenotypes. A
similar case is seen with mutations leading to either CIP or PEPD
(Cox et al., 2006; Fertleman et al., 2006). Both of these are
caused by mutations in NaV1.7, which is expressed in nocicep-
tive dorsal root ganglion and sympathetic ganglion neurons.
Loss of function of NaV1.7 leads to an inability to form action
potentials and, therefore, loss of pain sensation. Gain-of-func-
tion mutations, on the other hand, result in increased action
potential duration and therefore more synaptic transmission,
causing heightened pain perception and PEPD. Shifting the
gating profile of this channel so that it activates at more hyperpo-
larized potentials, thereby relaying normally nonpainful inputs as
painful, results in erythermelalgia (Dib-Hajj et al., 2005; Yanget al., 2004). Interestingly, this result is only the case in dorsal
root ganglion (DRG) neurons. NaV1.7 is also expressed in
sympathetic ganglion neurons, where at least the L858H muta-
tion instead leads to hypoexcitability rather than the hyperexcit-
ability seen with the same mutation in DRG neurons, better ex-
plaining the sympathetic symptoms of this disorder (Rush
et al., 2006). These disparate results are due to the presence
of NaV1.8 in DRG neurons. Alterations of gating are also
observed in NaV1.1 mutations leading to type 3 FHM. Here,
some mutations result in altered fast and slow inactivation,
which, when combined with promigraine conditions, seems to
lead to self-limiting hyperexcitability (Ceste`le et al., 2008).
Mutations in NaV1.1 do not only cause migraine; they can also
cause a number of epilepsy disorders, such as GEFS+ and
SMEI, as mentioned above (Catterall et al., 2010). The under-
standing of GEFS+ by the study of mutant NaV1.1 expressed in
nonneuronal cells has been complicated by the fact that there
is no theme to the results, with some mutations apparently re-
sulting in a gain of function and others in a loss of function.
The creation of mousemodels has helped to clarify these results.
The R1648H mutation, for example, results in altered kinetics in
both excitatory and inhibitory neurons, but these effects seem to
be sufficient only in leading to aberrant function in theGABAergic
interneurons, which then have reduced excitability (Martin et al.,Neuron 68, October 21, 2010 ª2010 Elsevier Inc. 285
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severe and generally lead to a complete loss of channel function.
As loss of sodium current should lead to hypoexcitability, it was
not at first apparent why this would lead to severe epilepsy.
Mouse models lacking NaV1.1 indicated that GABAergic inter-
neurons are preferentially affected by loss of NaV1.1, while excit-
atory neurons are spared. It seems, then, that like GEFS+, SMEI
mutations result in decreased GABAergic interneuron activity
(Yu et al., 2006). Patients with SMEI also have nonepileptic
phenotypes, such as ataxia. NaV1.1 is also present in Purkinje
cells, though it is not the only sodium channel expressed there.
While SMEImutations do not alter the threshold for action poten-
tial formation, they do alter some characteristics of the sodium
current and lead to altered firing rate. These alterations in
GABAergic output may be sufficient to account for cerebellum-
associated comorbidities and predict that the other SMEI co-
morbidities may be caused by similar mechanisms (Kalume
et al., 2007).
While most gain-of-function mutations alter gating, some
result in quite novel properties. The mutations in both NaV1.4
and CaV1.1 underlying hypoKPP are present in the voltage-
sensing S4 helix (Jurkat-Rott et al., 2009; Sokolov et al., 2007).
These mutations result in the creation of an alternate ion-con-
ducting pore through the S4 slide helix, termed a gating pore
current. For the NaV1.4 mutations, this current seems to conduct
protons or sodium, depending on the mutation; the fact that
CaV1.1 does not express well in a heterologous system has
made its mutations more difficult to study, though some insights
have recently been gained (Jurkat-Rott et al., 2009). In these
disorders, a cation leak in the presence of hypokalemia results
in the shift of the resting membrane potential to a more depolar-
ized second stable state, termed paradoxical depolarization.
Direct leakage of sodium seems to cause intracellular accumula-
tion and direct alteration of the restingmembrane potential, while
leakage of H+ indirectly results in accumulation of intracellular
sodium ions by activation of the Na+/H+ exchanger (Catterall,
2010). Not surprisingly, then, the amplitude of the gating pore
current inversely correlates with the severity of hypokalemia
required to elicit an attack.
Calcium Channel Disorders
As with sodium channels, mutations of calcium channels can be
either gain- or loss-of-function alleles. Mutation of CaV2.1, the
P/Q-type channel expressed throughout the brain, can result in
FHM type 1 (FHM1), EA type 2 (EA2), spinocerebellar ataxia
type 6 (SCA6), or a mixture of the three.
FHM1mutations lead to alteration of CaV2.1 kinetics such that
channels depolarize at more hyperpolarized potentials than
normal (e.g., R192Q) (Hans et al., 1999). Recent mouse models
have indicated that these CaV2.1 mutations in FHM1 lead to
enhanced excitatory, but not inhibitory, synaptic transmission
and increase the propensity for cortical spreading depression
(Pietrobon, 2010; Tottene et al., 2009). FHM1 mutations also
tend to result in decreased sensitivity to inhibition by G
protein-coupled receptors (Melliti et al., 2003; Serra et al.,
2009; Weiss et al., 2008). In general, then, these alterations likely
decrease the threshold for inducing cortical spreading depres-
sion. EA2 mutations, on the other hand, tend to result in
decreased current, often due to protein instability (e.g., G293R)286 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.(Wan et al., 2005). Many are, in fact, splicing or frameshift muta-
tions expected to result in total loss of function. SCA6 mutations
primarily result in a toxic gain of function involving CAG repeats
in the P-type splice form of the channel (Zhuchenko et al., 1997).
This form is highly expressed in Purkinje cells of the cerebellum,
where the mutations cause intracellular aggregates (Ishikawa
et al., 1999). While these channels can be functional, they tend
to form intracellular inclusions (Watase et al., 2008).
Voltage-Gated Potassium Channel Disorders
Therearealsoanumberof channelopathies related to thevoltage-
gated potassium channel. Examples include EA1 and benign
febrile neonatal convulsions type 1 and 2 (BFNC1 and BFNC2).
As potassium channels are vital in the downstroke of the action
potential, it is not surprising thatmutationsmight causeprolonged
action potentials and altered excitability of different neuronal
populations. In EA1, KV1.1 mutations lead to a drastic decrease
in currents, often at least partly due to improper trafficking.
Mutations such asV174F also result in activation atmoredepolar-
ized potentials, further compounding the effect (Browne et al.,
1994; Zerr et al., 1998). These defects in gating can also have
a dominant-negative effect on coexpressed wild-type subunits
(Zerr et al., 1998). KV1.1 is expressed in interneurons of the
cerebellum that alter Purkinje firing and cerebellum output. In
contrast, mutations in KV7.2 and KV7.3 that cause BFNC1 and
BFNC2 seem to result in haploinsufficiency (Biervert et al., 1998;
Lerche et al., 1999; Schroeder et al., 1998; Singh et al., 1998).
Chloride Channel Disorders
The chloride reversal potential in skeletal muscle plays a vital role
in setting the resting membrane potential. Not surprisingly, then,
drastic decrease in chloride permeability results in increased
membrane resistance, such that a given depolarizing input is
able to depolarize a greater surface area of membrane, and
altered resting membrane potential. For myotonia congenita to
occur, a large portion (90%) of chloride conductance must
be blocked (Furman and Barchi, 1978). Mutations in the skeletal
muscle chloride channel, ClC-1, can result in either a dominant
(Thomsen disease) or a recessive (Becker generalized myotonia)
form of myotonia congenita. These mutations tend to produce
either purely nonfunctional channels or channels that open at
a more depolarized potential such that the chloride conductance
is no longer able to compensate for depolarization caused by
potassium accumulation in the T-tubular system of skeletal
muscle, thus resulting in hyperexcitability (Duran et al., 2010).
Inward Rectifier Potassium Channel Disorders
Inward rectifier potassium (Kir) channels are a broadly expressed
family of 18 members (Kubo et al., 2005; Ryan et al., 2010). Each
of the four subunits of a functional channel is composed of two
transmembrane a helices (evolutionarily related to the S5 and
S6 transmembrane helices of voltage-gated potassium chan-
nels) and intracellular N and C termini (Figure 2). Like voltage-
gated channels, Kir channels can heteromultimerize. It is inter-
esting that to date, there are few neurologic disorders associated
with Kir channel mutations in humans. The best studied is ATS,
which is due to mutations in Kir2.1. The Kir2 family (Kir2.1–
Kir2.6), with the exception of Kir2.5, is a class of strong inward
rectifiers, meaning that channels can pass more current into
than out of a cell. Kir2.1 is particularly widely expressed; it is
found in the heart, brain, and skeletal muscle, among other
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alter its function in a variety of ways (Donaldson et al., 2004).
Some alter the ability of the channel to bind to PIP2 in the
membrane, which is required for channel opening. Others result
in haploinsufficiency or loss of function in a dominant-negative
manner through a variety of other mechanisms. In the heart,
Kir2.1 contributes significantly to the Ik1 current, which is respon-
sible, in part, for repolarization following the upstroke of an action
potential. ATS mutations lead to prolongation of the cardiac
action potential and thereby lead to arrhythmias. ATS mutations
likely lead to the observed periodic paralytic phenotype by
decreasing the clearance of potassium in the T-tubular system.
Timothy syndrome is another channelopathy affecting more
than one organ system. The causative gene encodes CaV1.2,
which is expressed in the heart but also in other tissues,
including the brain. These patients manifest multiorgan dysfunc-
tion, including lethal arrhythmias, syndactyly, immune defi-
ciency, congenital heart disease, intermittent hypoglycemia,
cognitive abnormalities, and autism (Splawski et al., 2004). It is
interesting that ATS and Timothy syndrome have overlapping
features, including cardiac arrhythmias, limb dysmorphisms,
and CNS features. In all patients characterized to date, Timothy
syndrome results from a de novomutation in CaV1.2 (G406R and
G402S) (Splawski et al., 2005; Splawski et al., 2004). Interest-
ingly, mutations in the alternatively spliced exon 8 lead to type
2 Timothy syndrome, which differs from the classical variant by
being primarily cardiac due to the preferential expression of
this splice form in the heart (Splawski et al., 2005).
A recently discovered disorder, alternately named SeSAME
syndrome (seizures, sensorineural deafness, ataxia, mental
retardation, and electrolyte imbalance) and EAST syndrome
(the presence of epilepsy, ataxia, sensorineural deafness, tubul-
opathy), is characterized by similar loss-of-function mutations in
Kir4.1 (Bockenhauer et al., 2009; Scholl et al., 2009). These
mutations cause a disorder characterized by salt wasting,
epilepsy, ataxia, and sensorineural deafness. These mutations
all lead to channels that are unable to pass current in the physi-
ologically relevant pH range (Reichold et al., 2010).
Ligand-Gated Ion Channel Disorders
Episodic disorders due to mutation of ligand-gated channels are
relatively rare. Examples include ADNFLE and a congenital
myasthenic syndrome, due to mutations in nicotinic acetylcho-
line receptors (nAChRs), and hyperekplexia, due to mutation in
a glycine receptor (GlyR). A likely reason for this paucity is that
the mutations in such widely expressed proteins may prove
lethal. Both nAChRs and GlyRs are pentameric in structure,
with five subunits asymmetrically surrounding a central pore
(Albuquerque et al., 2009; Lynch, 2004). The exact composition
of subunits in an nAChR can significantly alter the receptor’s
biochemical and biophysical properties. Mutations in CHRNA2,
CHRNA4, and CHRNB2 can result in ADNFLE. There have
been many contradictory studies involving these mutations,
but a common theme is that ADNFLE mutations seem to cause
a gain of function whereby nAChRs are more sensitive to activa-
tion by acetylcholine (Marini and Guerrini, 2007). Mutations in
a variety of pre- through postsynaptic neuromuscular junction
proteins, including many nAChR subunits, can also result in
congenital myasthenic syndrome (Engel et al., 2010). Thesemutations can broadly result in three alterations. First, they can
reduce expression, thereby degrading the fidelity of signal trans-
mission. Second, mutations can lead to a slowing of the decay of
nAChR currents, for example by altering the open or closed state
kinetics or the Ach dissociation time constant. These prolonged
openings then seem to lead to overloading of the postsynaptic
region of the endplate and to weakness. The third broad set of
alterations result in abnormally fast decay of nAChR currents
and result in the disorder as with mutations altering expression.
Mutations in a variety of GlyR subunits can result in hyperek-
plexia, characterized by an exaggerated startle response and
generalized weakness (Harvey et al., 2008; Lynch, 2004). Muta-
tions generally decrease the inhibitory input from GlyR, leading
to excessive excitation.
General Themes of Channelopathies
General themes from these findings include the exact expression
profile of a protein dictating the clinical phenotype of its muta-
tions. Most channelopathies affect only one organ system
because the associated protein is not expressed broadly. Chan-
nelopathies resulting from mutations in genes that are more
widely expressed are apparently less common, most likely
because they would be predicted to cause more severe or lethal
disorders. This general theme becomesmore complicated in the
brain, where mutated channels may have opposite effects on
different neuronal populations, as exemplified by the NaV1.7
mutations in erythermelalgia. Furthermore, the exact role that
the protein plays in action potential formation and information
transfer (e.g., synaptic transmission) can largely predict the
result of underlying mutations, which tend to produce prolonged
action potentials. Thus, most sodium channel mutations result in
aberrantly large sodium currents during depolarization or when
there would otherwise be no significant sodium current. Chloride
and potassium channels, on the other hand, tend to have muta-
tions that result in a loss of function, often in a dominant-negative
manner. Calcium channels tend to have mutations that alter
synaptic transmission. Whether the resulting increased action
potential duration results in eventual hypo- or hyperexcitability
is largely dependent on the severity of the alteration, with more
pronounced depolarizations resulting in hypoexcitability due to
inactivation of wild-type voltage-gated channels. In the brain, it
is the degree to which mutations affect excitatory or inhibitory
neurons that predicts whether a mutation results in aberrant
network hypo- or hyperexcitability.
Not All Episodic Neurological Disorders Are Due to Ion
Channel Mutations
All electrical disorders must ultimately result from altered
channel or membrane physiology, and mutations in ion channels
are one way of leading to such diseases. But an interesting new
direction of research on episodic disorders focuses not directly
on ion channels but on the structural proteins that control their
surface localization, targeting, and function. The canonical
example of this is LQT syndrome type 4, of which mutations of
the ubiquitously expressed Ankyrin-B are one cause (Hashemi
et al., 2009). Splice forms of Ankyrin-B result in proteins with
different subcellular distributions. Many of the Ankyrin-B muta-
tions result in a simple loss of function, whereas others seemNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 287
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varying degrees of mislocalization and altered expression of
ion channels and transporters, such as the Na/K ATPase and
the Na/Ca exchanger (Hashemi et al., 2009). These mutations
indicate the importance of subcellular localization in maintaining
normal function.
While many familial episodic neurological disorders are due to
mutations in either ion channels or structural proteins that affect
them, there is also emerging interest in proteins that seem to
more indirectly lead to episodic phenotypes. Examples of such
disorders are the audiogenic seizure (AGS)-susceptible pheno-
type of the Frings mouse and familial febrile seizures, auto-
somal-dominant lateral temporal epilepsy (ADLTE) and
paroxysmal nonkinesigenic dyskinesia (PNKD) in humans.
Presentation of a loud acoustic stimulus to a Frings mouse
induces a seizure phenotype including wild running followed by
tonic flexion and then tonic extension (Skradski et al., 2001).
This phenotype is not caused by an ion channel mutation, as
originally surmised, but by a mutation in a very large orphan G
protein-coupled receptor alternately called Mass1 and Vlgr1.
This same protein is alsomutated in some cases of familial febrile
seizures (Nakayama et al., 2002). Interestingly, both the mouse
and the human phenotypes are caused by early truncation of
the protein. The immense size of Mass1 has made its study diffi-
cult; how mutations in it lead to either of these phenotypes
remains an open question, though presumably its activation
modulates neuronal ion channels.
Another episodic neurological disorder reminiscent of a chan-
nelopathy is ADLTE, which is caused by mutations in LGI1 in
around 50% of cases (Nobile et al., 2009). ADLTE is character-
ized by partial seizures with auditory hallucinations. LGI1 func-
tions by interacting with the postsynaptic ADAM22 protein and
the presynaptic KV1 potassium channels (Fukata et al., 2010).
LGI1 can alter KV1 inactivation. The normal function of LGI1
seems to be to tune synaptic transmission, which is presumably
altered by ADLTE mutations.
PNKD is caused by mutations in a gene called Pnkd, whose
function is currently unknown (Lee et al., 2004). Interestingly,
the protein encoded by Pnkd is novel but shares homology
with a family of enzymes important in stress-response pathways.
These disorders open up new routes for the exploration of new
pathways that alter channel activity and synaptic release, which
might also prove useful in devising new treatments for other
neurologic disorders.
Ion Channel SNPs Can Be Disease Related
Understanding of the genetic etiology of neurological disorders
has led to an increased understanding of normal human vari-
ability, such as pain perception. As discussed above, mutations
in SCN9A can result in either extreme or complete loss of pain
perception. This led to the hypothesis that SNPs in SCN9Amight
lead to nonpathological differences in pain perception (Reimann
et al., 2010). Genotyping of numerous individuals with various
pain threshold scores indicated that those with a particular
SNP (A allele at SNP rs6746030) have increased pain scores to
a given noxious stimulus. Another recent example of such find-
ings is the relation of SNPs inCACNG2with chronic pain suscep-
tibility. CACNG2 encodes Stargazin, which is involved in regu-288 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.lating AMPA receptor trafficking and modulation. A number of
SNPs in this gene have been shown to be associated with
increased risk of postmastectomy chronic pain (Nissenbaum
et al., 2010). While these results have not been further validated
and the SNPs have not been characterized, they presumably
lead to altered plasticity following nerve injury.
Similar to this, study of the familial channelopathies has led to
the discovery of new risk alleles. Mutations in SCN5A lead to
a variety of cardiac arrhythmiadisorders. Aswithpainperception,
above, this led to the theory that commonSNPs inSCN5Amaybe
associatedwith risk for cardiac arrhythmia (Splawski et al., 2002).
Indeed, common SNPs in SCN5A are associated with an
increased risk of arrhythmia. The Y1102 variant, for example, is
a common allele in the African American population and is signif-
icantly enriched in individuals with cardiac arrhythmia. This poly-
morphism results in slightly increased channel activation at more
hyperpolarized potentials. When combined with nongenetic risk
factors, such mild modifications seem to be sufficient to lead to
significantly increased rates of disease.
Study of Familial Channelopathies Helps in
Understanding Sporadic Channelopathies
While understanding of the genetics of familial episodic neuro-
logical disorders can help explain normal human variation (e.g.,
SCN9A SNPs and pain perception) and risk susceptibility (e.g.,
SCN5A and cardiac arrhythmia) and predict less apparent clin-
ical phenotypes (e.g., the expansion of the ATS phenotype pre-
dicted by the expression profile of Kir2.1), it can also serve as the
basis for probing sporadic episodic neurological disorders. A
recent example of this is thyrotoxic hypokalemic periodic paral-
ysis (TPP). TPP is clinically similar to hypoKPP but is concomi-
tant with thyrotoxicosis of any cause, treatment of which blocks
further attacks. Study of TPP has been hampered by the fact that
it is typically sporadic. Given the extensive knowledge of the
genetics and physiology of the familial periodic paralyses and
the striking clinical similarity between them and TPP, it was
hypothesized that TPP might also be a channelopathy. Conse-
quently, many skeletal muscle ion channel genes, whose
promoter regions harbored consensus sequences for regulation
by thyroid hormone, were screened for mutations. The Kir2.6 ion
channel was serendipitously found in this process, and muta-
tions were found in many cases of TPP (Ryan et al., 2010).
Kir2.6 is interesting in that it demonstrates many of the general
themes of familial channelopathies. First, stress in the form of
thyrotoxicosis and some other triggers, such as carbohydrate
loading, precipitate attacks. Our current understanding of the
pathophysiology of TPP is much less complete than for the
familial periodic paralyses, in part because Kir2.6 was discov-
ered only recently. In addition, in vitro experiments show
complex consequences of different mutations. First, Kir2.6
expression is upregulated by thyroid hormones. Second, some
of the mutations produce channels having normal kinetics under
basal conditions that are altered with increased thyroid
hormone. Furthermore, some mutations are predicted to alter
subcellular localization, reminiscent of mutations in structural
proteins discussed above, while at least one mutation causes
a loss of function, as is commonly seen in potassium channel
disorders. Knowledge of the familial channelopathies is likely
to prove useful in elucidating other such sporadic disorders.
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Autoimmune Channelopathies
Not all channelopathies are genetic in origin. An emerging group,
the autoimmune channelopathies, are due to antibodies against
ion channels rather than mutations in ion channels or proteins
that modify their localization or modulate their function (Lang
and Vincent, 2009). Examples of these include Lambert-Eaton
syndrome and Isaac’s syndrome (or neuromyotonia), which are
caused by antibodies against voltage-gated calcium and potas-
sium channels, respectively. Lambert-Eaton syndrome is char-
acterized by proximal muscle weakness with areflexia, while
neuromyotonia is characterized by abnormal muscle activity
that arises from neuronal hyperexcitability. More severe cases
of Isaac’s syndrome can also involve CNS symptoms such as
anxiety and memory loss.
Other examples of acquired channelopathies include autoanti-
bodies raised against either the AMPA receptor subunit GluR3 or
the NMDA receptor NR2B subunit in Rasmussen’s encephalitis,
a severe progressive epilepsy disorder typically arising in child-
hood and often leading to intellectual deterioration (Granata,
2003; Takahashi et al., 2005). A number of possible explanations
forRasmussen’s encephalitispathogenesishavebeenproposed,
suchas theantibody-binding-inducedpresentationof anagonist-
binding site with concomitant increases in AMPA receptor-medi-
ated current or complement-mediated cytotoxicity (in the case of
GluR3). It should be noted that not all cases of Rasmussen’s
encephalitis are associated with antibodies against GluR3 and
that such antibodies are seen in some cases of noninflammatory
epilepsy (Mantegazza et al., 2002; Wiendl et al., 2001).
Transcriptional Channelopathies
Not all acquired channelopathies are due to the creation of anti-
bodies against ion channels; transcriptional channelopathies
result from the aberrant transcription of an otherwise normal
gene (Waxman, 2001). Altered transcription can be due to any
cause, with two examples being peripheral nerve injury and
multiple sclerosis (MS). Peripheral nerve injury can result in
hyperexcitability of the regeneratedaxon that is due todecreased
expression of some sodium channels normally present and
increased expression of other sodium channels that are normally
silent. In dorsal root ganglion neurons, for example, NaV1.8 and
NaV1.9 are normally highly expressed (Waxman, 2001), whereas
NaV1.3 becomes the predominant form following axonal transec-
tion. These NaV1.3 channels recover more quickly from inactiva-
tion and lead to hyperexcitability. Themost profound alteration in
MS is neuronal demyelination. In the TAIEP rat model of MS, for
example, myelin degeneration in the cerebellum results in
increased expression of NaV1.8 in this tissue. While this may in
large part compensate for the loss of myelin, NaV1.8 channels
are slow to enter the inactive state and recover from this state
relatively quickly, suggesting that their increased expression in
Purkinje cells might lead to ataxia. In humans with MS, motor
axons in the median nerve show increased slow K+ current,
which is most readily explained by increased transcription of
the underlying current (Ng et al., 2008).
Conclusions
There are awide variety of episodic neurological disorders, many
of which are due to mutations in ion channels or proteins thatmodify their localization. Channelopathies result from a wide
array ofmutations, but they all result in a single consistent theme:
an increased ability to move normal cellular and/or network
excitability into a parallel aberrant excitability state (Figure 1).
While this state sometimes exists at a somewhat stable level
without the presence of an underlying mutation (e.g., cortical
spreading depression can be evoked in even wild-type mice
given sufficient KCl administration), these mutations seem to
result in either the aberrant state becoming more stable relative
to the normal state or the barrier to transitions from normal to
aberrant states being reduced. Homeostatic mechanisms,
then, are no longer capable of keeping the system within normal
parameters when stressed by a precipitant. Developing new
therapies targeting the transition into an aberrant state rather
than the specific mutated protein may prove useful.
In the channelopathies, mutations tend to lead to an increase
in action potential duration. Often this leads to simple hyperex-
citability, with the resulting phenotype dependent on the expres-
sion pattern of the underlying mutated protein. Consequently,
such mutations in muscle lead to myotonia, while mutations in
proteins from neurons involved in nociception result in increased
pain sensation. In the brain, it is a channel’s effects on the various
subtypes of neurons in a network that predict the resulting alter-
ation of network dynamics. Further alteration by the addition of
persistent currents results in even more depolarization and an
inability to reach threshold due to inactivation of wild-type
voltage-gated channels. Understanding these mechanisms
may prove useful in devising novel treatments, as selectively tar-
geting the mutated protein often proves difficult and other
proteins in the system may be more structurally unique.
Study of these familial variants is also helpful in elucidating
sporadic channelopathies such as TPP and the acquired chan-
nelopathies. Having already formed much of the framework for
understanding a physiological alteration, we are better able
both to predict the underlying pathophysiological cause and to
devise useful therapeutic strategies.
Important future directions in the field will be to elucidate how
precipitants result in the clinical phenotype. For some disorders,
such as hypokalemia triggering hypoKPP, this process is
becoming clearer, but this is not generally the case. It is also
not always clear how hormones interact with channelopathies
to alter the severity and prevalence. Thyrotoxicosis, for example,
is much more common among women than men, but TPP is
much more prevalent among men than women. Understanding
these interplays will prove important in fully understanding the
pathogenic mechanisms of the disease. Studies of mouse
models will be invaluable in these studies and will also serve to
increase our knowledge of normal physiology. Some diseases,
such as TPP, are not readily amenable to study by the creation
of an animal model. Instead, study of primary human tissue
and the use of computational models may be helpful.
For patients, the benefits from these studies will be multifold.
The discovery of underlying genetic causes aids in proper diag-
nosis, and therefore proper treatment, of diseases that can be
clinically quite similar. Future studies will likely find SNPs in these
genes associated with disease risk. While many such associa-
tions prove spurious, the linkage of these genes with known
familial disorders greatly increases the prior probability of suchNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 289
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Reviewfindings. The ability to reduce genetic heterogeneity during
enrollment into clinical trials should result in both more signifi-
cant scientific results and treatments that are better targeted
toward more genetically homogeneous subgroups of patients.
Finally, as genes encoding proteins that are not ion channels
are now being shown to cause some episodic disorders, new
pathways and targets for drug development are being identified.
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